The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition)

  • Lowest Price Guaranteed From USD 2,199

  • Published
    May 2015

  • Pages
    275

  • View Count
    3896

Example Insights

  1. More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug.
  2. Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien.
  3. Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market.
  4. DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma.
  5. Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts.
  6. The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics. 

Overview

Given the intricacy of the anatomy and physiology of the eye, it is quite challenging to deliver an ophthalmic drug effectively to a specific ocular site. Several barriers have to be overcome for a successful ocular drug delivery. These include dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva and drug permeation issues with respect to the cornea, sclera and choroid. Approximately 95% of the drug, in topical eye drops, is lost due to the aforementioned barriers.

The widening gap between the demand of novel treatments and supply of drugs/ systems is going to provide a major impetus to the sustained release ocular drug delivery market in the coming decade. Different ocular drug delivery systems have been devised for supplying drugs effectively to various parts of the eye. Contact lenses and punctal plugs are used to deliver drugs to the anterior segment of the eye while intravitreal implants and injectable particulate systems are used for drug delivery into the posterior segment of the eye. There are both advantages and disadvantages of the existing drug delivery systems; advancements are being made to enhance ocular bioavailability and retention time of the drug.

In the past few years, these implants and inserts have become one of the key focus areas of researchers and companies alike. Several venture capital firms have backed the smaller organizations working in this field. In addition, partnerships and collaborations have played a pivotal role in the advancement of the market.

 

Scope of the Report

The ‘Sustained Release Ocular Drug Delivery Systems, 2015 – 2025 (2nd edition)’ report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases.

The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry.

The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on where the ophthalmic drug delivery systemsmarket is headed in the short, mid and long term.

Chapter 3  provides a general introduction to the ophthalmic drug delivery market. We have discussed, in detail, the anatomy of the eye. The chapter also outlines details on different types of ocular drug delivery implants. In addition, several ocular indications, which are being targeted by sustained release implants, are also covered in this chapter.

Chapter 4  provides an overview of the ophthalmic drug delivery systems market with respect to the available marketed technologies and companies active in the field. We have provided a detailed pipeline of systems that are either marketed or are under clinical/ preclinical development. The chapter includes pipeline analysis by phase of development, system type, and indications targeted. It also covers the sustained release systems that are currently being evaluated by academic researchers and universities. In addition, we have also provided information on gene therapies that are being developed to provide a controlled treatment to several ocular indications.

Chapter 5  provides detailed profiles of 13 systems which are marketed and/ or arein late stages of clinical development (Phase II and Phase III). These profiles cover information on underlying technologies, development history, principal features (size of the implant, drug elution rate, life of the implant, related patents and intellectual property, nature of the insert) and current status of development. For each system, we have also estimated the future sales potential over the next ten years. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present different tracks of industry’s evolution.

Chapter 6  reviews the 13 leading companies which are active in the area of ophthalmology sustained release drug delivery technology. Each company profile includes information on the company overview, financial performance, marketed / pipeline systems, fundings, partnerships, and recent developments.

Chapter 7  provides information on several investment instances which have driven research in the area of sustained release ocular drug delivery systems. These investments are a testament to the growing interest of different stakeholders in this industry.

Chapter 8  covers details on the recent partnerships which have taken place in this industry. We have discussed the various partnerships models in existence and the most common forms of deals / agreements which have evolved over time.

Chapter 9  provides our analysis of the strengths, weaknesses, opportunities and threats in the ophthalmology drug delivery systems market, capturing the key elements likely to influence future growth.

Chapter 10  is a collection of transcripts based on our discussion with some of the leading players in the industry. Examples of companies interviewed include Neurotech Pharmaceuticals, Mati Therapeutics, On Demand Therapeutics and Euclid Systems. 

Chapter 11  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 12 and 13  are appendices, which provide tabulated data and a list of companies mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Overview
3.1. Introduction
3.2. Structure of the Eye
 
3.3. Ocular Drug Delivery Systems
3.3.1. Implantable Ocular Drug Delivery Systems
3.3.2. Particulate Drug Delivery Systems
 
3.4. Ocular Drug Delivery: Commonly Targeted Ophthalmic Disorders
3.4.1. Age-related Macular Degeneration
3.4.2. Cytomegalovirus Retinitis
3.4.3. Diabetic Retinopathy
3.4.4. Diabetic Macular Edema
3.4.5. Glaucoma
3.4.6. Ocular Infection
3.4.7. Uveitis
3.4.8. Retinal Vein Occlusion
 
4. MARKET OVERVIEW
4.1. Scope
4.2. Limited Marketed Ocular Systems for Sustained Drug Delivery
4.3. pSivida is the Key Technology Provider
4.4. Sustained Release Ocular Drug Delivery Systems: Pipeline Analysis
4.4.1. Distribution by Phase of Development
4.4.2. Distribution by Nature of Drug Delivery Systems
4.4.3. Distribution by Intraocular Placement of Drug Delivery Systems
4.4.4. Distribution by Indication Targeted
4.4.5. Novel Implants for Ocular Drug Delivery
4.4.6. Initial Focus on Anti-Inflammatory Drugs
4.4.7. Glaucoma: The Next Big Opportunity?
4.4.8. Universities’ Interest in Ocular Sustained Drug Delivery Systems Market
4.5. Life Cycle Management Tool
4.6. Gene Therapy
 
5. PRODUCT PROFILES AND SALES FORECAST
5.1. Chapter Overview
5.2. Methodology and Assumptions
5.3. Overall Market Size and Forecast, 2015-2025
 
5.4. Retisert (Bausch & Lomb, Inc)
5.4.1. Product Overview
5.4.2. Development and Approval History
5.4.3. Product Specifications
5.4.4. Manufacturing of Retisert
5.4.5. Product Advantages
5.4.6. Associated Risks
5.4.7. Historical Sales
5.4.8. Sales Forecast, 2015-2025
 
5.5. Iluvien (Alimera Sciences)
5.5.1. Product Overview
5.5.2. Development and Approval History
5.5.3. Product Specifications
5.5.4. Manufacturing of Iluvien
5.5.5. Product Advantages
5.5.6. Associated Risks
5.5.7. Iluvien Contraindications
5.5.8. Historical Sales
5.5.9. Competition
5.5.10. Opportunity for Iluvien
5.5.11. Sales Forecast, 2015-2025
 
5.6. Ozurdex (Allergan)
5.6.1. Product Overview
5.6.2. Development and Approval History
5.6.3. Product Specifications
5.6.4. Product Advantages
5.6.5. Associated Risks
5.6.6. Historical Sales and Reimbursement
5.6.7. Competition
5.6.8. Sales Forecast, 2015-2025
 
5.7. IBI-10090 (Icon Bioscience)
5.7.1. Product Specifications
5.7.2. Current Status of Development
5.7.3. Clinical Trial Results
5.7.4. Advantages
5.7.5. Competition
5.7.6. Sales Forecast, 2015-2025
 
5.8. OTX-DP (Ocular Therapeutix)
5.8.1. Product Specifications
5.8.2. Current Status of Development
5.8.3. Clinical Trial Results
5.8.4. Product Advantages
5.8.5. Competition
5.8.6. Sales Forecast, 2015-2025
 
5.9. Medidur (pSivida)
5.9.1. Product Specifications
5.9.2. Current Status of Development
5.9.3. Clinical Trial Results
5.9.4. Competition
5.9.5. Sales Forecast, 2015-2025
 
5.10. Bimatoprost Sustained Release Implant (Allergan)
5.10.1. Product Specifications
5.10.2. Current Status of Development
5.10.3. Clinical Trial Results
5.10.4. Product Advantages
5.10.5. Competition
5.10.6. Sales Forecast, 2015-2025
 
5.11. NT-501 (Neurotech Pharmaceuticals)
5.11.1. Product Specifications
5.11.2. Current Status of Development
5.11.3. Phase II Clinical Trial Results
5.11.4. Product Advantages
5.11.5. Sales Forecast, 2015-2025
 
5.12. Punctal Plug Delivery System (Mati Therapeutics)
5.12.1. Product Specifications
5.12.2. Current Status of Development
5.12.3. Clinical Trial Results
5.12.4. Product Advantages
5.12.5. Competition
5.12.6. Sales Forecast, 2015-2025
 
5.13. OTX-TP (Ocular Therapeutix)
5.13.1. Product Specifications
5.13.2. Current Status of Development
5.13.3. Clinical Trial Results
5.13.4. Product Advantages
5.13.5. Competition
5.13.6. Sales Forecast, 2015-2025
 
5.14. NT-503 (Neurotech Pharmaceuticals)
5.14.1. Product Specifications
5.14.2. Current Status of Development
5.14.3. Phase I Clinical Trial Results
5.14.4. Product Advantages
5.14.5. Sales Forecast, 2015-2025
 
5.15. Unnamed, Novadur (Allergan)
5.15.1. Product Specifications
5.15.2. Current Status of Development
5.15.3. Clinical Trial Results
5.15.4. Sales Forecast, 2015-2025
 
5.16. ProDex (Taiwan Liposome Company)
5.16.1. Product Specifications
5.16.2. Current Status of Development
5.16.3. Product/ Technology Advantages
 
5.17. Comparative Analysis of Sustained Release Ocular Drug Delivery Systems
5.17.1. Biodegradable Systems
5.17.2. Non-Biodegradable Systems
 
6. COMPANY PROFILES
6.1. Chapter Overview
 
6.2. pSivida
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Durasert and Tethadur Technology
6.2.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.2.5. Collaborations
6.2.6. Recent Developments
 
6.3. Allergan
6.3.1. Company Overview
6.3.2. Financial Performance
6.3.3. Novadur Technology
6.3.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.3.5. Collaborations
6.3.6. Recent Developments
 
6.4. Icon Bioscience
6.4.1. Company Overview
6.4.2. Funding
6.4.3. Verisome Technology
6.4.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.4.5. Recent Developments
 
6.5. Ocular Therapeutix
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Funding
6.5.4. Hydrogel Technology
6.5.5. Sustained Release Ocular Drug Delivery Systems Portfolio
6.5.6. Recent Developments
 
6.6. Neurotech Pharmaceuticals
6.6.1. Company Overview
6.6.2. Funding
6.6.3. Encapsulated Cell Technology
6.6.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.6.5. Collaborations
 
6.7. Santen Pharmaceutical
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. Ophthalmology: Leading Marketed Drugs
6.7.4. CHRONIJECT Microsphere Technology
6.7.5. Sustained Release Ocular Drug Delivery Systems Portfolio
6.7.6. Collaborations
 
6.8. Aciont Inc.
6.8.1. Company Overview
6.8.2. Funding
6.8.3. Visulex Technology
6.8.4. Sustained Release Ocular Drug Delivery Systems Portfolio
 
6.9. Envisia Therapeutics
6.9.1. Company Overview
6.9.2. Funding
6.9.3. Sustained Release Ocular Drug Delivery Technology
6.9.4. Sustained Release Ocular Drug Delivery Systems Portfolio
 
6.10. GrayBug
6.10.1. Company Overview
6.10.2. Funding
6.10.3. Sustained Release Ocular Drug Delivery Technology
6.10.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.10.5. GrayBug: In The News
 
6.11. Innocore Pharmaceuticals
6.11.1. Company Overview
6.11.2. Sustained Release Ocular Drug Delivery Technology
6.11.3. Sustained Release Ocular Drug Delivery Systems Portfolio
6.11.4. Collaborations
 
6.12. OHR Pharmaceuticals
6.12.1. Company Overview
6.12.2. Financial Performance
6.12.3. SKS Ocular Sustained Release Technology
6.12.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.12.5. Collaborations
 
6.13. PolyActiva
6.13.1. Company Overview
6.13.2. Funding
6.13.3. Sustained Release Ocular Drug Delivery Technology
6.13.4. Sustained Release Ocular Drug Delivery Systems Portfolio
6.13.5. Collaborations
6.14. TheraKine
6.14.1. Company Overview
6.14.2. Sustained Release Ocular Drug Delivery Technology
6.14.3. Sustained Release Ocular Drug Delivery Systems Portfolio
6.14.4. Collaborations
 
7. VENTURE CAPITAL SUPPORT
7.1. Chapter Overview
7.2. Instances of Investments / Grants in Sustained Release Ocular Drug Delivery Market
7.3. Growing Venture Capitalist Interest
7.4. Distribution of Funding Instances by Type of Funding
7.5. Distribution by Total Amount of Investment in a Category
 
8. RECENT PARTNERSHIPS
8.1. Chapter Overview
8.1.1. Partnership Models / Agreements
8.1.2. Collaborations Amongst Stakeholders are on a Rise
8.1.3. Product/ Technology Development, Acquisitions and Product/ Technology Licensing Are Preferred Modes of Collaboration
8.1.4. Most Active Companies in Sustained Release Ocular Drug Delivery Systems
 
9. SWOT ANALYSIS
9.1. Chapter Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats
 
10. INTERVIEW TRANSCRIPTS
10.1. Quinton Oswald, President and CEO, Neurotech Pharmaceuticals
10.2. Bob Butchofsky, Founder and CEO, Mati Therapeutics
10.3. John Santini, President and CEO, On Demand Therapeutics
10.4. Michael A Ross, Chief Executive Officer and Allan Kaplan, Chief Financial Officer, Euclid Systems
10.5. Other Anonymous Respondents
 
11. CONCLUSION
11.1. With A Huge Potential, Market Likely to Evolve Rapidly in Mid-Long Term
11.2. Ophthalmic Indications and Improved Patient Compliance Are Amongst the Several Growth Drivers
11.3. Key Emerging Technologies: Novel Methods for Efficient Drug Delivery
11.4. A Number of Opportunities Outweigh Existing Challenges
11.5. Concluding Remarks
 
12. APPENDIX 1: TABULATED DATA
 
13. APPENDIX 2: LIST OF COMPANIES

List of Figures

Figure 4.1 Ocular Drug Delivery Implants: Approval Timeline
Figure 4.2 Sustained Release Ocular Drug Delivery Systems: Distribution by Phase of Development
Figure 4.3 Sustained Release Ocular Drug Delivery Systems: Distribution by Nature of System
Figure 4.4  Sustained Release Ocular Drug Delivery Systems: Distribution by Site of Intraocular Placement
Figure 4.5  Sustained Release Ocular Drug Delivery Systems: Distribution by Target Indication
Figure 4.6  Sustained Release Ocular Drug Delivery Systems, University Research: Distribution by Target Indication
Figure 4.7  Lucentis Sales, 2010-2014 (USD Million)
Figure 4.8  Lumigan Sales, 2010-2014 (USD Million)
Figure 5.1  Overall Sales Forecast, Short-Mid Term (2014 – 2020), USD Million (Base Scenario)
Figure 5.2  Overall Sales Forecast, Mid- Long term (2020 – 2025), USD Million (Base Scenario)
Figure 5.3  Retisert Sales, 2010 – 2014 (USD Million)
Figure 5.4  Retisert Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.5  Retisert Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.6  Iluvien Sales, 2013-2014 (USD Million)
Figure 5.7  IVT Treated DME: US Market Share by Leading Drugs (%)
Figure 5.8  Iluvien Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.9  Iluvien Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.10  Ozurdex Development Timeline
Figure 5.11  Ozurdex Sales, 2010 – 2014 (USD Million)
Figure 5.12  Ozurdex Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.13  Ozurdex Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.14  IBI-10090 Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
Figure 5.15  IBI-10090 Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.16  OTX-DP Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.17  Retisert, Iluvien, Ozurdex and Medidur: Percentage Share of Patients Reported to Have Developed IOP
Figure 5.18  Medidur Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.19  Bimatoprost Sustained Release Implant Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.20  NT-501 Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.21  PPDS Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.22  OTX-TP Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
Figure 5.23  NT-503 Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.24  Unnamed (Novadur) Sales Forecast: Long Term, USD Million (Base Scenario)
Figure 5.25  Biodegradable Sustained Release Ocular DDS: Comparative Analysis
Figure 5.26  Non-Biodegradable Sustained Release Ocular DDS: Comparative Analysis
Figure 6.1 pSivida Revenues, 2012-Q3 2015 (USD ‘000)
Figure 6.2  Allergan Revenues, 2010-2014 (USD Million)
Figure 6.3 Allergan Revenues: Distribution by Business Segment, 2012-2014 (USD Million)
Figure 6.4  Allergan Specialty Pharmaceuticals Revenues: Distribution by Therapeutic Areas, 2014 (USD Million)
Figure 6.5  Allergan Revenues: Distribution by Sub-Segments of Medical Devices, 2014 (USD Million)
Figure 6.6  Allergan: Sales of Leading Marketed Ophthalmic Drugs (USD Million), 2013-2014
Figure 6.7  Icon Bioscience: Milestone Chart
Figure 6.8  Ocular Therapeutix Revenues, 2014 (USD’000)
Figure 6.9 Neurotech Pharmaceuticals: Milestone Chart
Figure 6.10  Santen Revenues: 2009-Q3 2015 (JPY Million)
Figure 6.11  Santen Revenues: Distribution by Business Segments, 2012-2014 (JPY Million)
Figure 6.12 Santen Revenues: Distribution by Sub-Segments of Pharmaceutical Business, 2014 (JPY Million)
Figure 6.13 Santen Revenues: Distribution by Sub-Segments of Other Businesses, 2014 (JPY Million)
Figure 6.14  OHR Pharmaceuticals: Operating Expenses, 2010- Q1 2015 (USD ‘000)
Figure 7.1  Sustained Release Ocular DDS Funding Instances: Cumulative Investments by Year, 2003-2015
Figure 7.2 Sustained Release Ocular DDS Funding Instances: Distribution by Categories
Figure 7.3  Sustained Release Ocular DDS Funding Instances: Distribution by Amount Invested in a Category (USD Million)
Figure 8.1  Sustained Release Ocular DDS Partnerships: Cumulative Partnerships by Year, 2001-2014
Figure 8.2 Sustained Release Ocular DDS Partnerships: Distribution by Type of Partnership
Figure 8.3  Sustained Release Ocular DDS Partnerships: Major Stakeholders
Figure 11.1 Ocular Drug Delivery Implants: Market Landscape And Growth Drivers
Figure 11.2  Sustained Release Ocular DDS Market, 2015, 2020, 2025 (USD Million)

List of Tables

Table 3.1 Eye: Description of Tissue Layers
Table 4.1 Availability of Ocular Drug Delivery Implants in the US and Europe
Table 4.2  Sustained Release Ocular Drug Delivery Systems: Pipeline
Table 4.3 Sustained Release Ocular Drug Delivery Systems: Research Projects at Universities
Table 4.4 Gene Therapies under Development for Ocular Diseases
Table 5.1  Current Development Phase and Expected Launch Year of Drug Delivery Systems (Phase II and Higher)
Table 5.2  Comparison of Iluvien with Currently Available Drugs for DME
Table 5.3  Vision Loss Associated with DME, Number of Patients in the US and Major EU Countries, 2012
Table 5.4  Market Potential for Iluvien in the US
Table 5.5  Approval of Ozurdex in Different Geographies
Table 5.6  IBI-10090: Completed Clinical Trials
Table 5.7  IBI-10090: Clinical Trial Results
Table 5.8  IBI-10090 and Marketed Topicals: Comparison of Anterior Chamber Cell Count
Table 5.9  IBI10090: Competitive Landscape
Table 5.10  OTX-DP: Ongoing Clinical Trials
Table 5.11  OTX-DP: Clinical Trial Results
Table 5.12  Medidur: Status of Development
Table 5.13  Medidur: Competitive Landscape
Table 5.14  Medidur and Available Drugs for Posterior Uveitis: Comparative Analysis
Table 5.15  Bimatoprost Implant: Patents
Table 5.16  NT-501: Ongoing Clinical Trials
Table 5.17  PPDS: Patents
Table 5.18  OTX-TP: Clinical Trials
Table 5.19  OTX-TP: Efficacy Results
Table 5.20  NT-503: Key Features
Table 5.21  NT503: Clinical Trial Result
Table 5.22  Brimonidine Implant: Patents
Table 5.23  Unnamed (Novadur): Clinical Trials
Table 5.24  Biodegradable Sustained Release Ocular DDS: Comparative Analysis
Table 5.25  Non-Biodegradable Sustained Release Ocular DDS: Comparative Analysis
Table 6.1  pSivida: Sustained Release Ocular DDS Pipeline
Table 6.2  pSivida: Revenues Received from Alimera Sciences (2009-2013), USD Million
Table 6.3  pSivida: Revenues Received from Restated Pfizer Agreement (2009-2013), USD Million
Table 6.4  Marketing Authorization Approvals: Iluvien (2014-2015)
Table 6.5 Allergan: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.6 Icon Bioscience: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.7  Ocular Therapeutix: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.8 Neurotech Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.9 NT-501: Orphan Drug and Fast Track Designations
Table 6.10 Neurotech: Research Collaborations
Table 6.11  Santen: Pipeline of Ophthalmology Drugs/ Systems
Table 6.12  Aciont Inc: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.13  Envisia Therapeutics: Company Overview
Table 6.14 Envisia Therapeutics: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.15 GrayBug: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.16 GrayBug: In The News
Table 6.17 Innocore Pharmaceuticals: Company Overview
Table 6.18  Innocore Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.19 OHR Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.20  PolyActiva: Company Overview
Table 6.21 PolyActiva: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 6.22 TheraKine: Company Overview
Table 6.23 TheraKine: Sustained Release Ocular Drug Delivery Systems Pipeline
Table 7.1  List of Funding Rounds / Grants and Investors Involved
Table 8.1 Sustained Release Ocular Drug Delivery Systems: List of Partnerships
Table 9.1 Sustained Release Ocular Drug Delivery Systems: SWOT Analysis
Table 9.2 Development of Sustained Release Ocular Systems: Example Venture Capital Funding Instances
Table 12.1  Sustained Release Ocular Drug Delivery Systems: Distribution by Phase of Development
Table 12.2  Sustained Release Ocular Drug Delivery Systems: Distribution by Nature of System
Table 12.3  Sustained Release Ocular Drug Delivery Systems: Distribution by Site of Intraocular Placement
Table 12.4  Sustained Release Ocular Drug Delivery Systems: Distribution by Target Indication
Table 12.5  Sustained Release Ocular Drug Delivery Systems, University Research: Distribution by Target Indication
Table 12.8  Overall Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Base Scenario)
Table 12.9  Overall Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Base Scenario)
Table 12.10  Overall Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Conservative Scenario)
Table 12.11  Overall Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Conservative Scenario)
Table 12.12  Overall Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Optimistic Scenario)
Table 12.13  Overall Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Optimistic Scenario)
Table 12.14  Retisert Sales, 2010-2014 (USD Million)
Table 12.15  Retisert Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Base Scenario)
Table 12.16  Retisert Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Base Scenario)
Table 12.17  Retisert Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Conservative Scenario)
Table 12.18  Retisert Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Conservative Scenario)
Table 12.19  Retisert Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Optimistic Scenario)
Table 12.20  Retisert Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Optimistic Scenario)
Table 12.21  Iluvien Sales, 2013-2014 (USD Million)
Table 12.22  IVT Treated DME: US Market Share by Leading Drugs (%)
Table 12.23  Iluvien Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Base Scenario)
Table 12.24  Iluvien Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Base Scenario)
Table 12.25  Iluvien Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Conservative Scenario)
Table 12.26  Iluvien Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Conservative Scenario)
Table 12.27  Iluvien Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Optimistic Scenario)
Table 12.28  Iluvien Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Optimistic Scenario)
Table 12.30  Ozurdex Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Base Scenario)
Table 12.31  Ozurdex Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Base Scenario)
Table 12.32  Ozurdex Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Conservative Scenario)
Table 12.33  Ozurdex Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Conservative Scenario)
Table 12.34  Ozurdex Sales Forecast, Short-Mid Term (2015 – 2020), USD Million (Optimistic Scenario)
Table 12.35  Ozurdex Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Optimistic Scenario)
Table 12.36  IBI-10090 Sales Forecast, Short-Mid Term (2016 – 2020), USD Million (Base Scenario)
Table 12.37  IBI-10090 Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Base Scenario)
Table 12.38  IBI-10090 Sales Forecast, Short-Mid Term (2016 – 2020), USD Million (Conservative Scenario)
Table 12.39  IBI-10090 Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Conservative Scenario)
Table 12.40  IBI-10090 Sales Forecast, Short-Mid Term (2016 – 2020), USD Million (Optimistic Scenario)
Table 12.41  IBI-10090 Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Optimistic Scenario)
Table 12.42  OTX-DP Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Base Scenario)
Table 12.43  OTX-DP Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Conservative Scenario)
Table 12.44  OTX-DP Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Optimistic Scenario)
Table 12.45  Retisert, Iluvien, Ozurdex and Medidur: % Share of Patients Reported to Have Developed IOP
Table 12.46  Medidur Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Base Scenario)
Table 12.47  Medidur Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Conservative Scenario)
Table 12.48  Medidur Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Optimistic Scenario)
Table 12.49  Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Base Scenario)
Table 12.50  Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Conservative Scenario)
Table 12.51  Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Optimistic Scenario)
Table 12.52  NT-501 Forecast, Mid-Long Term (2019 – 2025), USD Million (Base Scenario)
Table 12.53  NT-501 Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Conservative Scenario)
Table 12.54  NT-501 Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Optimistic Scenario)
Table 12.55  PPDS Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Base Scenario)
Table 12.56  PPDS Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Conservative Scenario)
Table 12.57  PPDS Sales Forecast, Mid-Long Term (2019 – 2025), USD Million (Optimistic Scenario)
Table 12.58  OTX-TP Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Base Scenario)
Table 12.59  OTX-TP Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Conservative Scenario)
Table 12.60  OTX-TP Sales Forecast, Mid-Long Term (2020 – 2025), USD Million (Optimistic Scenario)
Table 12.61  NT-503 Sales Forecast, Mid-Long Term (2021 – 2025), USD Million (Base Scenario)
Table 12.62  NT-503 Sales Forecast, Mid-Long Term (2021 – 2025), USD Million (Conservative Scenario)
Table 12.63  NT-503 Sales Forecast, Mid-Long Term (2021 – 2025), USD Million (Optimistic Scenario)
Table 12.64  Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 – 2025), USD Million (Base Scenario)
Table 12.65  Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 – 2025), USD Million (Conservative Scenario)
Table 12.66  Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 – 2025), USD Million (Optimistic Scenario)
Table 12.67  pSivida Revenues, 2012- Q3 2015 (USD’000)
Table 12.68  Allergan Revenues, 2010- 2014 (USD Million)
Table 12.69  Allergan Revenues: Distribution by Business Segment, 2012-2014 (USD Million)
Table 12.70  Allergan Specialty Pharmaceuticals Revenues: Distribution by Therapeutic Areas, 2014 (USD Million)
Table 12.71  Allergan Revenues: Distribution by Sub Segments of Medical Devices, 2014 (USD Million)
Table 12.72  Allergan: Sales for Leading Marketed Ophthalmic Drugs, 2013-2014 (USD Million)
Table 12.73  Ocular Therapeutix Revenues, 2014 (USD’ 000)
Table 12.74  Santen Revenues, 2009- Q3 2015 (JPY Million)
Table 12.75  Santen Revenues: Distribution by Business Segments, 2012-2014 (JPY Million)
Table 12.76  Santen Revenues: Distribution by Sub-Segments of Pharmaceutical Business, 2013-2014 (JPY Million)
Table 12.77  Santen Revenues: Distribution by Sub-Segments of Other Businesses, 2013-2014 (JPY Million)
Table 12.78  OHR Pharmaceuticals: Operating Expenses, 2010-Q1 2015 (USD’000)
Table 12.79  Sustained Release Ocular DDS Funding Instances: Cumulative Investments by Year, 2003-2015
Table 12.80  Sustained Release Ocular DDS Funding Instances: Distribution by Categories
Table 12.81  Sustained Release Ocular DDS Funding Instances: Distribution by Amount Invested In a Category (USD Million)
Table 12.82  Sustained Release Ocular DDS: Cumulative Partnerships by Year, 2001-2014
Table 12.83  Sustained Release Ocular DDS Partnerships: Distribution by Type of Partnership
Table 12.84  Sustained Release Ocular DDS Partnerships: Major Stakeholders

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3i Plc
  2. AbbVie
  3. Abell Foundation
  4. Aciont, Inc.
  5. Actavis Plc
  6. Aerie Pharmaceutical
  7. Ain Shams University, Cairo, Egypt
  8. Alcon
  9. Alimera Sciences
  10. Allergan
  11. Alliance Medical Products Inc
  12. Alpha Associates
  13. Amgen Inc.
  14. Amorphex Therapeutics
  15. Apax Partners
  16. Ascension Health Ventures
  17. Atlas Venture
  18. Auritec Pharmaceuticals
  19. Avida Group
  20. Bausch & Lomb
  21. Baxter Venture
  22. Bayer Healthcare
  23. BCN Peptides
  24. Ben Venue Laboratories
  25. BioLight Israeli Life Sciences Investments Ltd.
  26. Brandon Biosciences
  27. Brecon Pharmaceuticals Ltd
  28. Brown Advisory
  29. Burrill and Company
  30. Byron Chemical Company
  31. Caja Navarra
  32. Canaan Partners
  33. Can-Fite BioPharma
  34. Catania University, Catania, Italy
  35. Centre for Eye Research Australia (CERA)
  36. Chang Gung University
  37. Chiron Vision Corporation
  38. Chongqing Medical University
  39. Clave Mayor
  40. Control Delivery Systems Inc.
  41. Corporación CAN
  42. Cullen Eye Institute, Baylor College of Medicine
  43. Domain Associates
  44. Duke Reading Center
  45. Duke University Medical Center
  46. Economic Committee for Health Products
  47. Enigma Therapeutics
  48. Envisia Therapeutics
  49. Ergo Equity
  50. ESBATech (a Biomedical Research Unit of Alcon)
  51. Euclid Systems
  52. EVS Glaucoma Therapeutics
  53. FARMABIOS SpA
  54. Federal University of Minas Gerais
  55. Flextronics International Ltd
  56. ForSight Labs
  57. Genentech
  58. GIMV
  59. GP Pharm
  60. GrayBug
  61. Hatteras Venture Partners
  62. Health Ventures
  63. Hercules Technology Growth Capital
  64. Hospital Research Center, Linkoping University
  65. Icon Bioscience
  66. IIT Roorkee
  67. Innocore
  68. Institute for Advanced Chemistry of Catalonia
  69. Institute of Nanoscience and Nanotechnology, Barcelona
  70. Intersouth Partners
  71. InterWest Partners
  72. Intrinsiq
  73. Inveready
  74. Johns Hopkins University School of Medicine
  75. Kyoto University, Faculty of Medicine
  76. le Venture Partners
  77. Lowy Medical Research Institute (LMRI)
  78. Maryland Biotechnology Center
  79. Maryland Venture
  80. Mati Therapeutics
  81. Mayflower
  82. Medicines and Healthcare products Regulatory Agency
  83. Melbourne University
  84. Memorial Sloan Kettering Cancer Center
  85. Merlin Biosciences
  86. MIT, Boston
  87. Monash University
  88. Morningside Group
  89. Nanomi
  90. Nanyang Technological University, Singapore
  91. National Eye Institute
  92. National Institute for Health and Care Excellence (NICE)
  93. National Institutes of Health Clinical Center
  94. National Tsing Hua University
  95. Navarra Civic Banking
  96. Neurotech Pharma
  97. New Enterprise Associates
  98. Nexus Medical Partners
  99. Nishi Eye Hospital, Osaka, Japan
  100. Novagali Pharma
  101. Novartis
  102. Nuclear Magnetic Resonance Unit, Barcelona
  103. Oakwood Laboratories
  104. OctoPlus
  105. Ocular Therapeutix
  106. Oculex Pharmaceuticals
  107. OHR Pharmaceuticals
  108. On Demand Therapeutics
  109. OncoSil Medical
  110. Ora Inc.
  111. Pappas Ventures
  112. Pfizer
  113. Polaris Ventures
  114. Polyactiva
  115. Pound Capital
  116. ProRetina Therapeutics
  117. pSivida Corp
  118. QLT Inc.
  119. Rainbow Biosciences
  120. Real Fleece FCR
  121. Regeneron
  122. Replenish, Inc.
  123. Roche
  124. Sanofi
  125. Santen
  126. Sanwa Kagaku Kenkyusho
  127. Sao Paulo State University
  128. School of Pharmacy, West Virginia University
  129. Signet Healthcare Partners
  130. Singapore Eye Research Institute
  131. SKS Ocular LLC
  132. Sodena (Navarra Development Society )
  133. Sparta LLC
  134. Specialized Therapeutics
  135. SV Life Sciences
  136. Taiwan Liposome Company
  137. The EMMES Corporation
  138. TheraKine
  139. Tulane University Medical Center
  140. United Centers for Advanced Research and Translational Medicine (ART)
  141. University of Barcelona
  142. University of California
  143. University of Cincinnati
  144. University of Colorado
  145. University of Florida
  146. University of Miami
  147. University of Nebraska
  148. University of Ottawa, Ottawa
  149. University of Pittsburgh
  150. University of Porto
  151. University of Waterloo
  152. Valeant Pharmaceuticals
  153. Venrock
  154. Versant Ventures
  155. Wakefield Group
  156. Wayne State University
  157. West LB
  158. Wilmer Eye Institute at Johns Hopkins University
  159. World Health Organization
  160. XOMA
  161. Yuwa capital

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,199

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com